Form 4: Amphastar Pharmaceuticals Executive Yakob Liawatidewi Reports Stock Transactions

Yakob Liawatidewi, EVP Corp Admin Center at Amphastar Pharmaceuticals, reports the withholding of shares for tax liability and shares acquired through the employee stock purchase plan.

Summary

• On June 4, 2024, Yakob Liawatidewi, EVP Corp Admin Center at Amphastar Pharmaceuticals, reported transactions involving common stock.
• 272 shares were withheld to cover tax liabilities related to the vesting of restricted stock units (RSUs) at a price of $42.22.
• Liawatidewi also acquired 432 shares under the company's 2014 Employee Stock Purchase Plan on May 31, 2024.
• Following these transactions, Liawatidewi directly owns 74,938 shares and indirectly owns 2,459 shares through the Yakob and Sunmoon Trust dated July 25, 2013, for which she serves as a trustee.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document simply reports routine stock transactions by an executive.

Positives

• The acquisition of shares through the Employee Stock Purchase Plan indicates confidence in the company's future.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives regarding their holdings of company stock.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders.
• The transactions reported are typical for executives who receive stock-based compensation and participate in employee stock purchase plans.
• Similar filings can be observed for executives at comparable pharmaceutical companies like Teva Pharmaceuticals, Mylan (now Viatris), and Hikma Pharmaceuticals.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are routine and do not represent a significant change in ownership.

Key Dates